• Explore /
  • Poster
  • / Reassessing the net health benefit (NHB) of FDA approved cancer drugs with evolution of evidence using the American Society of Clinical Oncology Value Framework (ASCO-VF).

Reassessing the net health benefit (NHB) of FDA approved cancer drugs with evolution of evidence using the American Society of Clinical Oncology Value Framework (ASCO-VF).

Abstract Poster

Authors

null

Seanthel Delos Santos

Sunnybrook Research Institute, Toronto, ON, Canada

Seanthel Delos Santos , Noah Witzke , Vanessa Sarah Arciero , Amanda Putri Rahmadian , Louis Everest , Kelvin K. Chan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Discussion Session

Session Title

Health Services Research and Quality Improvement

Track

Quality Care/Health Services Research

Sub Track

Value/Cost of Care

Citation

J Clin Oncol 38: 2020 (suppl; abstr 7011)

DOI

10.1200/JCO.2020.38.15_suppl.7011

Abstract #

7011

Poster Bd #

283

Abstract Disclosures

Similar Posters

First Author: J. Carlos Tapia

First Author: Ademola Samuel Ojo

Poster

2014 ASCO Annual Meeting

Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval.

Systematic review of a personalized strategy in cancer clinical trials leading to FDA approval.

First Author: Denis Leonardo Fontes Jardim

First Author: Chimezie Ubbaonu